HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $34.00 price objective on the stock.
Checkpoint Therapeutics Stock Performance
Checkpoint Therapeutics stock opened at $2.06 on Monday. The firm’s fifty day moving average price is $1.77 and its 200-day moving average price is $1.94. The stock has a market cap of $73.52 million, a P/E ratio of -0.74 and a beta of 1.13. Checkpoint Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $3.62.
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) last issued its earnings results on Friday, May 10th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.04. On average, analysts predict that Checkpoint Therapeutics will post -1.29 earnings per share for the current year.
Institutional Investors Weigh In On Checkpoint Therapeutics
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
Further Reading
- Five stocks we like better than Checkpoint Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Progress Software Stock Back in the Green After Beating Forecasts
- P/E Ratio Calculation: How to Assess Stocks
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.